Do statins affect androgen levels in men? Results from the Boston Area Community Health Survey

Cancer Epidemiology Biomarkers and Prevention

Volumn 16, Issue 8, 2007, Pages 1587-1594

  Hall, Susan A ^a   Page, Stephanie T ^b   Travison, Thomas G ^a   Montgomery, R Bruce ^b   Link, Carol L ^a   McKinlay, John B ^a  

^a NEW ENGLAND RESEARCH INSTITUTES   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ANDROGEN; ANTIARRHYTHMIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBONATE DEHYDRATASE INHIBITOR; CARDIAC GLYCOSIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; FLECAINIDE; FLUINDOSTATIN; FLUTAMIDE; HYDRALAZINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LUTEINIZING HORMONE; MEVINOLIN; MINOXIDIL; OLMESARTAN; PENTOXIFYLLINE; PRASTERONE; PRASTERONE SULFATE; PRAVASTATIN; ROSUVASTATIN; SEX HORMONE BINDING GLOBULIN; SIMVASTATIN; TELMISARTAN; TESTOSTERONE; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG;

ADULT; AGE DISTRIBUTION; AGED; BODY MASS; CANCER RISK; CARDIOVASCULAR DISEASE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; PUBLIC HEALTH; REVIEW; STATISTICAL SIGNIFICANCE; TESTOSTERONE BLOOD LEVEL; UNITED STATES;

ADULT; AGE FACTORS; AGED; ANDROGENS; ANTICHOLESTEREMIC AGENTS; BODY MASS INDEX; BOSTON; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; CONFOUNDING FACTORS (EPIDEMIOLOGY); CROSS-SECTIONAL STUDIES; DEHYDROEPIANDROSTERONE SULFATE; DIABETES COMPLICATIONS; EPIDEMIOLOGIC STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LUTEINIZING HORMONE; MALE; MIDDLE AGED; POLYPHARMACY; POPULATION SURVEILLANCE; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE; TIME FACTORS;

EID: 34548081675     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-07-0306     Document Type: Review

References (52)

1. IMShealth.com [homepage on the internet]. IMS Health reports 5.4 percent dollar growth in 2005 U.S. prescription sales. Norwalk: IMS Health Incorporated [updated 2006 Feb 22; cited 2007 May 22]. Available from: http://www.imshealth. com/ims/portal/front/articleC/0,2777,6599_3665_77180090,00.html.
2. Slone Epidemiology Center. Patterns of medication use in the United States, 2005: a report from the Slone survey. Boston (MA): Boston University; 2006 [updated 2006 Aug 29; cited 2007 May 22]. Available from: http://www.bu.edu/slone/SloneSurvey/AnnualRpt/SloneSurveyWebReport2005.pdf.
3. Miller GE, Stagnitti MN. Statistical Brief #97: Trends in statin use in the civilian noninstitutionalized Medicare population, 1997 and 2002. Rockville (MD): Agency for Healthcare Research and Quality [updated 2005 September; cited 2007 May 22]. Available from: http://www.meps.ahrq.gov/mepsweb/data_files/ publications/st97/stat97.pdf#xml=http://207.188.212.220/cgi-bin/texis/webinator/ search/pdfhi.txt?query=statin+use&pr=MEPSFULLSITE&prox=page&rorder= 500&rprox=500&rdfreq=500&rwfreq=500&rlead=500&sufs= 0&order=r&cq=&id=465298e541.
4. American Society of Health-System Pharmacists. HMG-CoA reductase inhibitors. In: McEvoy GK, editor. AHFS drug information 2006. Bethesda: American Society of Health-System Pharmacists, Inc.; 2006. p. 1674.
5. Moorman PG, Hamilton RJ. Statins and cancer risk: what do we know and where do we go from here? Epidemiology 2007;18:194-6.
6. Coogan PF, Rosenberg L, Strom BL. Statin use and the risk of 10 cancers. Epidemiology 2007;18:213-9.
7. Coogan PF, Rosenberg L, Palmer JR, Strom BL, Zauber AG, Shapiro S. Statin use and the risk of breast and prostate cancer. Epidemiology 2002;13:262-7.
8. Platz EA, Leitzmann MF, Visvanathan K, et al. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 2006;98:1819-25.
9. Dobs AS, Miller S, Neri G, et al. Effects of simvastatin and pravastatin on gonadal function in male hypercholesterolemic patients. Metabolism 2000;49:115-21.
10. Hyyppa MT, Kronholm E, Virtanen A, Leino A, Jula A. Does simvastatin affect mood and steroid hormone levels in hypercholesterolemic men? A randomized double-blind trial. Psychoneuroendocrinology 2003;28:181-94.
11. Mohr BA, Guay AT, O'Donnell AB, McKinlay JB. Normal, bound and nonbound testosterone levels in normally ageing men: results from the Massachusetts Male Ageing Study. Clin Endocrinol 2005;62:64-73.
12. Liu PY, Death AK, Handelsman DJ. Androgens and cardiovascular disease. Endocr Rev 2003;24:313-40.
13. McKinlay JB, Link CL. Measuring the urologic iceberg: design and implementation of the Boston Area Community Health (BACH) Survey. Eur J Urol 2007;52:389-96.
14. Litman HJ, Bhasin S, Link CL, Araujo AB, McKinlay JB. Serum androgen levels in black, Hispanic, and white men. J Clin Endocrinol Metab 2006;91:4326-34.
15. Sodergard R, Backstrom T, Shanbhag V, Carstensen H. Calculation of free and bound fractions of testosterone and estradiol-17β to human plasma proteins at body temperature. J Steroid Biochem 1982;16:801-10.
16. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999;84:3666-72.
17. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2006;91:1995-2010.
18. Kelley KE, Kelley TP, Kaufman DW, Mitchell AA. The Slone Drug Dictionary: a research driven pharmacoepidemiology tool. Pharmacoepidemiol Drug Saf 2003;12:168-9.
19. Diver MJ, Imtiaz KE, Ahmad AM, Vora JP, Fraser WD. Diurnal rhythms of serum total, free and bioavailable testosterone and of SHBG in middle-aged men compared with those in young men. Clin Endocrinol 2003;58:710-7.
20. Washburn RA, Smith KW, Jette AM, Janney CA. The Physical Activity Scale for the Elderly (PASE): development and evaluation. J Clin Epidemiol 1993;46:153-62.
21. Green LW. Manual for scoring socioeconomic status for research on health behavior. Public Health Rep 1970;85:815-27.
22. Turvey CL, Wallace RB, Herzog R. A revised CES-D measure of depressive symptoms and a DSM-based measure of major depressive episodes in the elderly. Int Psychogeriatr 1999;11:139-48.
23. Cochran WG. Sampling techniques. New York (NY): John Wiley and Sons; 1977.
24. Research Triangle Institute. SUDAAN Language Manual Release 9.0. Research Triangle Park (NC): Research Triangle Institute; 2004.
25. Rothman KJGS. Modern epidemiology. 2nd ed. Philadelphia: Lippincott-Raven Publishers; 1998. p. 256-7.
26. Dobs AS, Schrott H, Davidson MH, et al. Effects of high-dose simvastatin on adrenal and gonadal steroidogenesis in men with hypercholesterolemia. Metabolism 2000;49:1234-8.
27. Bohm M, Herrmann W, Wassmann S, Laufs U, Nickenig G. Does statin therapy influence steroid hormone synthesis? Z Kardiol 2004;93:43-8.
28. Plymate SR, Matej LA, Jones RE, Friedl KE. Inhibition of sex hormone-binding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin. J Clin Endocrinol Metab 1988;67:460-4.
29. Katsuki A, Sumida Y, Murashima S, et al. Acute and chronic regulation of serum sex hormone-binding globulin levels by plasma insulin concentrations in male noninsulin-dependent diabetes mellitus patients. J Clin Endocrinol Metab 1996;81:2515-9.
30. U.S. Centers for Disease Control and Prevention. National diabetes fact sheet: United States, 2005. Washington (DC): U.S. Department of Health and Human Services, Centers for Disease Control and Prevention [updated 2007 Mar 25 September; cited 2007 May 22]. Available from: http://www.cdc.gov/diabetes/pubs/ pdf/ndfs_2005.pdf.
31. Birkeland KI, Hanssen KF, Torjesen PA, Vaaler S. Level of sex hormone-binding globulin is positively correlated with insulin sensitivity in men with type 2 diabetes. J Clin Endocrinol Metab 1993;76:275-8.
32. Haffner SM, Shaten J, Stern MP, Smith GD, Kuller L. Low levels of sex hormone-binding globulin and testosterone predict the development of non-insulin-dependent diabetes mellitus in men. MRFIT Research Group. Multiple Risk Factor Intervention Trial. Am J Epidemiol 1996;143:889-97.
33. Kupelian V, Page ST, Araujo AB, Travison TG, Bremner WJ, McKinlay JB. Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab 2006;91:843-50.
34. Lindstedt G, Lundberg PA, Lapidus L, Lundgren H, Bengtsson C, Bjorntorp P. Low sex-hormone-binding globulin concentration as independent risk factor for development of NIDDM. 12-yr follow-up of population study of women in Gothenburg, Sweden. Diabetes 1991;40:123-8.
35. Stellato RK, Feldman HA, Hamdy O, Horton ES, McKinlay JB. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study. Diabetes Care 2000;23:490-4.
36. Bataille VPB, Evans A, Amouyel P, et al. Sex hormone-binding globulin is a major determinant of the lipid profile: the PRIME study. Atherosclerosis 2005;179:369-73.
37. Marks LS, Mazer NA, Mostaghel E, et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA 2006;296:2351-61.
38. Mohler JL, Gregory CW, Ford OH III, et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004;10:440-8.
39. Page ST, Lin DW, Mostaghel EA, et al. Persistent intraprostatic androgen concentrations after medical castration in healthy men. J Clin Endocrinol Metab 2006;91:3850-6.
40. Pelletier G, Luu-The V, El-Alfy M, Li S, Labrie F. Immunoelectron microscopic localization of 3β-hydroxysteroid dehydrogenase and type 5 17β-hydroxysteroid dehydrogenase in the human prostate and mammary gland. J Mol Endocrinol 2001;26:11-9.
41. Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM. Statins and cancer prevention. Nat Rev Cancer 2005;5:930-42.
42. Cyrus-David MS, Weinberg A, Thompson T, Kadmon D. The effect of statins on serum prostate specific antigen levels in a cohort of airline pilots: a preliminary report. J Urol 2005;173:1923-5.
43. Zhuang L, Kim J, Adam RM, Solomon KR, Freeman MR. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest 2005;115:959-68.
44. Mehta JL, Bursac Z, Hauer-Jensen M, Fort C, Fink LM. Comparison of mortality rates in statin users versus nonstatin users in a United States veteran population. Am J Cardiol 2006;98:923-8.
45. Johnson RE, Vollmer WM. Comparing sources of drug data about the elderly. J Am Geriatr Soc 1991;39:1079-84.
46. Kaneta S, Satoh K, Kano S, Kanda M, Ichihara K. All hydrophobic HMG-CoA reductase inhibitors induce apoptotic death in rat pulmonary vein endothelial cells. Atherosclerosis 2003;170:237-43.
47. Cauley JA, McTiernan A, Rodabough RJ, et al. Statin use and breast cancer: prospective results from the Women's Health Initiative. J Natl Cancer Inst 2006;98:700-7.
48. Boudreau DM, Yu O, Miglioretti DL, Buist DS, Heckbert SR, Daling JR. Statin use and breast cancer risk in a large population-based setting. Cancer Epidemiol Biomarkers Prev 2007;16:416-21.
49. Sivaprasad U, Abbas T, Dutta A. Differential efficacy of 3-hydroxy-3-methylglutaryl CoA reductase inhibitors on the cell cycle of prostate cancer cells. Mol Cancer Ther 2006;5:2310-6.
50. Duncan RE, El-Sohemy A, Archer MC. Statins and cancer development. Cancer Epidemiol Biomarkers Prev 2005;14:1897-8.
51. Sprague J, Wood M. Breast cancer prevention: time for randomized controlled trials with statins. Arch Intern Med 2006;166:1143-4.
52. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statins and cancer risk: a meta-analysis. JAMA 2006;295:74-80.